TP53 and diffuse large B-cell lymphoma: The data presented in this manuscript argue for the need for improved and more practical risk-stratification models for patients with DLBCL and show the potential for the use of <i>TP53</i> mutational status for prognostication and, in prospect, treatment stratification in DLBCL.